表紙
市場調査レポート

トランスサイレチン:パイプライン製品の分析

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 251567
出版日 ページ情報 英文 76 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
トランスサイレチン:パイプライン製品の分析 Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H1 2016
出版日: 2016年06月28日 ページ情報: 英文 76 Pages
概要

当レポートでは、トランスサイレチンの開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

トランスサイレチンの概要

治療薬の開発

トランスサイレチン:開発中の製品 - 開発段階別

トランスサイレチン:開発中の製品 - 治療範囲別

トランスサイレチン:開発中の製品 - 適応症別

トランスサイレチン:パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

トランスサイレチン:企業で開発中の製品

トランスサイレチン:大学/機関で開発中の製品

トランスサイレチン:治療薬の評価

  • 単剤療法/併用療法製品別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

トランスサイレチンの治療薬開発に従事している企業

  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics, Inc
  • Neurimmune Holding AG
  • Pfizer Inc.
  • Prothena Corporation Plc
  • Regeneron Pharmaceuticals, Inc.
  • SOM Innovation Biotech SL

薬剤プロファイル

休止中のプロジェクト

主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC0074TDB

Summary

Global Markets Direct's, 'Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H1 2016', provides in depth analysis on Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted pipeline therapeutics.

The report provides comprehensive information on the Transthyretin (ATTR or Prealbumin or TBPA or TTR), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Transthyretin (ATTR or Prealbumin or TBPA or TTR)
  • The report reviews Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Transthyretin (ATTR or Prealbumin or TBPA or TTR)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Transthyretin (ATTR or Prealbumin or TBPA or TTR) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) Overview
  • Therapeutics Development
    • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Products under Development by Stage of Development
    • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Products under Development by Therapy Area
    • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Products under Development by Indication
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Products under Development by Companies
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Products under Development by Universities/Institutes
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Companies Involved in Therapeutics Development
    • Alnylam Pharmaceuticals, Inc.
    • Arcturus Therapeutics, Inc
    • Neurimmune Holding AG
    • Pfizer Inc.
    • Prothena Corporation Plc
    • Regeneron Pharmaceuticals, Inc.
    • SOM Innovation Biotech SL
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Drug Profiles
    • ALN-TTRsc02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EDE-1307 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • inotersen sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LUNAR-TTR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Transthyretin for Amyloidosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NI-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotides to Inhibit Transthyretin for Amyloidosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • patisiran - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • revusiran - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tafamidis meglumine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tolcapone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Dormant Projects
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Featured News & Press Releases
    • Jun 09, 2016: Alnylam Initiates Phase 1 Clinical Trial for ALN-TTRsc02, an Investigational RNAi Therapeutic for the Treatment of TTR-Mediated Amyloidosis
    • May 26, 2016: Ionis Pharmaceuticals Provides Update on IONIS-TTR Rx Program
    • Apr 20, 2016: Alnylam Reports Complete 18-Month Data from Ongoing Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN)
    • Apr 07, 2016: Ionis Pharmaceuticals Provides Update on IONIS-TTRRX Program
    • Feb 01, 2016: Alnylam Completes Enrollment in APOLLO Phase 3 Study with Patisiran, an Investigational RNAi Therapeutic for Patients with Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
    • Dec 17, 2015: Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis
    • Nov 12, 2015: SOM Biotech and Vall d'Hebron successfully complete a clinical trial in patients with TTR amyloidosis
    • Nov 03, 2015: Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension Studies for Patisiran in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
    • Nov 03, 2015: Isis Pharmaceuticals Reports an Update on ISIS-TTR Rx, Including Positive Data from Multiple Clinical Studies, Presented at the EC-ATTR Meeting
    • Nov 03, 2015: Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension Studies for Revusiran, in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
    • Oct 27, 2015: Isis Pharmaceuticals to Host Webcast to Review ISIS-TTR Data Presented at 1st European Congress of Hereditary ATTR Amyloidosis and Provide Phase 3 Development Plan Update
    • Oct 14, 2015: Alnylam Demonstrates Continued Commitment to Transthyretin-Mediated Amyloidosis Patients with Advancement of ALN-TTRsc02, an Investigational RNAi Therapeutic with Potential for Low Volume, Once Quarterly, Subcutaneous Dose Regimen
    • Oct 01, 2015: 1st European Congress on Hereditary ATTR Amyloidosis
    • Sep 28, 2015: Alnylam and Collaborators Report First-Ever Evidence that Patisiran Reduces Pathogenic, Misfolded Transthyretin Monomers and Oligomers in TTR-Mediated Amyloidosis Patients with Familial Amyloidotic Polyneuropathy
    • Sep 15, 2015: Phase IIa Clinical Trial for TTR Amyloidosis successfully completed
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016
  • Pipeline by Arcturus Therapeutics, Inc, H1 2016
  • Pipeline by Neurimmune Holding AG, H1 2016
  • Pipeline by Pfizer Inc., H1 2016
  • Pipeline by Prothena Corporation Plc, H1 2016
  • Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
  • Pipeline by SOM Innovation Biotech SL, H1 2016
  • Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top